Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder
- PMID: 17236837
- DOI: 10.1016/j.bone.2006.11.023
Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder
Abstract
Bisphosphonate-related osteonecrosis of the jaws (BON), first described in 2003, is gaining importance due to the increasing indication spectrum of bisphosphonate therapy [S. Takeyama, M. Ito, H. Shinoda, A novel bisphosphonate, TRK-530, for periodontitis, Bone 38 (2006) 31-31; M. Tagil, A. W-Dahl, J. Astrand, D. Little, S. Toksvig-Larsen, Decreasing the catabolic response by a single bisphosphonate infusion shortens the healing time in hemicallotasis operations, Bone 38 (2006) 84-85; E. Rodriguez, M.C. Duran, L.M. Rodriguez, R. Ros, M.R. Aleman, M. Rodriguez-Gaspar, A.M. Lopez, E. Garcia-Valdecasas, F. Santolaria, Intravenous (IV) bisphosphonates for osteopenic cancer survivor women: an alternative treatment, Bone 38 (2006) 72-73; D.G. Little, K. Ward, P. Kiely, M.C. Bellemore, J. Briody, C.T. Cowell, Bisphosphonate rescue in distraction osteogenesis: a case series, Bone 38 (2006) 80-80; R. Marx, Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic, J. Oral Maxillofac. Surg. 61 (2003) 1115-1118]. BON patients suffering from varying bony defects and symptoms are extremely restricted in their quality of life. Due to a limited knowledge of the aetiology of BON efficient evidence-based treatment strategies are lacking. Until now 23 patients with bisphosphonate-related osteonecrosis have been admitted to the Department of Cranio-Maxillofacial Surgery of the University of Zurich. A complete history has been recorded. All patients underwent clinical and radiographic examination. CT scans and MRI have been performed in selected cases. All patients had in common that, before signs of BON were observed, a local traumatic incidence had occurred. All patients showed signs of infection which could be remarkably reduced by antibacterial treatment. Furthermore, the period of bisphosphonate treatment was found to be one of the significant factors causing bisphosphonate-related osteonecrosis of the jaws. The aetiology of BON appears to depend on multiple factors: period and type of bisphosphonate therapy and trauma paving the way for an invasion of pathogens. Because evidence based therapy protocols for complete remodelling of bone defect are still missing, prevention in bisphosphonate-treated patients seems to be of utmost importance. A close interdisciplinary collaboration is required.
Similar articles
-
Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.Todays FDA. 2008 Aug;20(8):38-41, 43-6. Todays FDA. 2008. PMID: 18767452
-
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.J Oral Maxillofac Surg. 2005 Nov;63(11):1567-75. doi: 10.1016/j.joms.2005.07.010. J Oral Maxillofac Surg. 2005. PMID: 16243172
-
Bisphosphonates and osteonecrosis of the jaws.J Dent Educ. 2008 Aug;72(8):919-29. J Dent Educ. 2008. PMID: 18676801 Review.
-
Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases.J Oral Maxillofac Surg. 2008 Feb;66(2):223-30. doi: 10.1016/j.joms.2007.09.019. J Oral Maxillofac Surg. 2008. PMID: 18201600
-
A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.Clin Ther. 2007 Aug;29(8):1548-58. doi: 10.1016/j.clinthera.2007.08.008. Clin Ther. 2007. PMID: 17919538 Review.
Cited by
-
Porphyromonas gingivalis Induces Bisphosphonate-Related Osteonecrosis of the Femur in Mice.Front Cell Infect Microbiol. 2022 Jun 22;12:886411. doi: 10.3389/fcimb.2022.886411. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35811676 Free PMC article.
-
Histomorphometric Effects of 2% Risedronate Gel on Calvarial Bone Defects in Rabbits.J Dent (Shiraz). 2021 Mar;22(1):14-20. doi: 10.30476/DENTJODS.2020.82926.1032. J Dent (Shiraz). 2021. PMID: 33681418 Free PMC article.
-
Phosphate functionalization and enzymatic calcium mineralization synergistically enhance oligo[poly(ethylene glycol) fumarate] hydrogel osteoconductivity for bone tissue engineering.J Biomed Mater Res A. 2020 Mar;108(3):515-527. doi: 10.1002/jbm.a.36832. Epub 2019 Nov 26. J Biomed Mater Res A. 2020. PMID: 31702863 Free PMC article.
-
Bisphosphonates in multiple myeloma: an updated network meta-analysis.Cochrane Database Syst Rev. 2017 Dec 18;12(12):CD003188. doi: 10.1002/14651858.CD003188.pub4. Cochrane Database Syst Rev. 2017. PMID: 29253322 Free PMC article. Review.
-
Carnosic acid attenuates RANKL-induced oxidative stress and osteoclastogenesis via induction of Nrf2 and suppression of NF-κB and MAPK signalling.J Mol Med (Berl). 2017 Oct;95(10):1065-1076. doi: 10.1007/s00109-017-1553-1. Epub 2017 Jul 4. J Mol Med (Berl). 2017. PMID: 28674855
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
